PBYI vs EXEL

For growth investors, Exelixis, Inc.

(EXEL) is the stronger pick with 7. 0% revenue growth year-over-year, versus -0. 9% for Puma Biotechnology, Inc. (PBYI). Puma Biotechnology, Inc. (PBYI) offers the better valuation at 11. 9x trailing P/E (29. 0x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Puma Biotechnology, Inc.

(PBYI) is the cheapest at 11. 9x versus Exelixis, Inc. at 16. 6x. On forward P/E, Exelixis, Inc. is actually cheaper at 14. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +84. 0%, compared to -25. 8% for Puma Biotechnology, Inc. (PBYI). Over 10 years, the gap is even starker: EXEL returned +833. 5% versus PBYI's -70. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exelixis, Inc.

(EXEL) is the lower-risk stock at 0. 80β versus Puma Biotechnology, Inc. 's 1. 11β — meaning PBYI is approximately 39% more volatile than EXEL relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 22% for Puma Biotechnology, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exelixis, Inc.

(EXEL) is pulling ahead at 7. 0% versus -0. 9% for Puma Biotechnology, Inc. (PBYI). On earnings-per-share growth, the picture is similar: Exelixis, Inc. grew EPS 58. 0% year-over-year, compared to -1. 6% for Puma Biotechnology, Inc.. Over a 3-year CAGR, EXEL leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus 13. 6% for Puma Biotechnology, Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus 16. 3% for PBYI. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Exelixis, Inc.

(EXEL) trades at 14. 0x forward P/E versus 29. 0x for Puma Biotechnology, Inc. — 15. 1x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +833. 5% 10Y return). Both have compounded well over 10 years (EXEL: +833. 5%, PBYI: -70. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.